Abbott Laboratories Finalizes $20 Billion Multi-Tranche Debt Offering to Fund Exact Sciences Acquisition

summarizeSummary

Abbott Laboratories has finalized a $20 billion multi-tranche debt offering, detailing the specific terms and interest rates for notes maturing between 2029 and 2066, primarily to finance the $21 billion acquisition of Exact Sciences Corporation.

check_boxKey Events

• Finalizes $20 Billion Debt Offering

  Abbott Laboratories is issuing $20 billion in unsecured, unsubordinated notes across eight tranches with maturities ranging from 2029 to 2066, including floating rate and fixed rate notes with interest rates from 3.700% to 5.600%.

• Funds Exact Sciences Acquisition

  The net proceeds from this offering, estimated at approximately $19.8 billion, will primarily be used to fund the consideration for the $21 billion acquisition of Exact Sciences Corporation, repay its indebtedness, and for general corporate purposes.

• Significant Increase in Debt

  This offering will increase Abbott's total long-term debt from $12.9 billion to $32.9 billion on an as-adjusted basis, reflecting a substantial increase in leverage to finance the acquisition.

• Special Mandatory Redemption Clause

  The notes include a special mandatory redemption clause, requiring Abbott to redeem outstanding notes at 101% of principal plus accrued interest if the Exact Sciences acquisition is not consummated by February 17, 2027, or a later agreed date.

auto_awesomeAnalysis

This filing formalizes the terms of a substantial $20 billion debt offering, which was previously announced as finalized in an FWP on February 24, 2026. The proceeds are earmarked to fund the $21 billion acquisition of Exact Sciences Corporation, repay its existing debt, and for general corporate purposes. This significant capital raise will substantially increase the company's long-term debt from $12.9 billion to $32.9 billion on an as-adjusted basis. The successful execution of this large-scale financing demonstrates Abbott's strong access to capital and commitment to its strategic growth initiatives, particularly the Exact Sciences acquisition. Investors should monitor the integration of Exact Sciences and the impact of increased leverage on future financial performance.